Published on 10 May 2024 on Simply Wall St. via Yahoo Finance
Earnings Miss: Pacira BioSciences, Inc. Missed EPS By 17% And Analysts Are Revising Their Forecasts
Investors in Pacira BioSciences, Inc. (NASDAQ:PCRX) had a good week, as its shares rose 9.3% to close at US$29.86 following the release of its quarterly results. It was not a great result overall. While revenues of US$167m were in line with analyst predictions, earnings were less than expected, missing statutory estimates by 17% to hit US$0.19 per share. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
See our latest analysis for Pacira BioSciences
